Introduction {#s1}
============

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in the world and is regarded as a severe public health concern.[@b1] The overall prevalence of NAFLD is approximately 25% worldwide and is 23%, 31% and 27% in Europe, South America and Asia, respectively.[@b2]--[@b4] Many factors contribute to the development of NAFLD, such as aging, hyperlipidemia, insulin resistance, type 2 diabetes, diet, genetics and so on.[@b5]--[@b8] Accumulated lines of evidence have suggested that coronary artery disease (CAD) plays an important role in the progression of NAFLD and is associated with the severity of NAFLD.

CAD has become the most important cause of mortality among NAFLD patients.[@b9] Although some defects of liver biopsy exist, such as invasive, sample errors and operator dependence, it remains the gold standard for diagnosis of NAFLD.[@b10],[@b11] In recent years, some noninvasive diagnostic methods have been developed and their effects have been tested in different countries and populations. Genome-wide association studies (GWAS) have identified several important single nucleotide polymorphism (SNP) sites which are tightly associated with the risk of development of NAFLD; these include *PNPLA3* rs738409, *TM6SF2* rs58542926, and *LYPLAL1* rs12137855.[@b12] In consideration of the differences of genetic background of NAFLD patients, it is necessary to identify the relationship of gene polymorphisms with the risk of NAFLD in different countries and races.

Glucokinase (GCK) is a phosphorylating enzyme which can regulate hepatic glucose metabolism and activate hepatic lipogenesis.[@b13] The *GCKR* gene encodes the glucokinase regulatory protein (GCKRP), which can bind to GCK allosterically and regulate the activity of GCK.[@b14] In 2011, Speliotes *et al.*[@b15] identified the *GCKR* rs780094 by GWAS as a significant SNP site associated with the risk of NAFLD. Subsequent studies in different districts reported controversial conclusions of *GCKR* rs780094 in NAFLD. The *GCKR* rs780094 T allele was found to be tightly associated with susceptibility to NAFLD in Americans and Malaysians, acting as a risk factor for NAFLD.[@b15],[@b16] However, no significant association between *GCKR* rs780094 and the risk of NAFLD was observed in the community-based study in Suzhou and Shanghai, and in obese adolescents in Beijing, China.[@b17]--[@b20] On the contrary, Lin *et al.*[@b21] reported that *GCKR* rs780094 was associated with an increased risk of NAFLD in obese children in Taiwan.[@b22] Therefore, large-scale population-based studies in different districts are needed to investigate the effect of *GCKR* rs780094 on the development of NAFLD in China.

In addition, GWAS analyses conducted in Finnish, Swedish and Danish populations found a strong linkage disequilibrium of *GCKR* rs780094 with *GCKR* rs1260326.[@b23],[@b24] In Japan, Kawaguchi *et al.*[@b25] found that *GCKR* rs1260326 was a significant risk factor for the development of NAFLD. In France, Petit *et al.*[@b26] reported that *GCKR* rs1260326 influences the liver fat content in patients with type 2 diabetes. Di *et al.*[@b27] reported that *GCKR* rs1260326 could increase the liver fat content, although the detailed role of GCKR rs1260326 in NAFLD remains controversial. Besides, Simons *et al.*[@b28] conducted a meta-analysis to investigate the relationship of *GCKR* polymorphisms with the risk of CAD, and a tight association of *GCKR* variants with the risk of CAD was observed.

In consideration of the unclear effects of *GCKR* rs780094 and rs1260326 on NAFLD in Chinese, and the tight association of CAD and NAFLD, it is of interest to explore the effects of *GCKR* rs780094 and rs1260326 on the development of NAFLD and the development of CAD in NAFLD patients from this population.

The aim of this study was to explore the relationship between *GCKR* gene polymorphisms (rs780094 and rs1260326) with the risk of NAFLD, the risk of CAD in NAFLD patients in a Chinese Northern Han population, and the effects of *GCKR* rs780094 and rs1260326 on the levels of serum lipid profiles.

Methods {#s2}
=======

Subjects {#s2-1}
--------

This case-control study was conducted according to the principles of the Declaration of Helsinki and its appendices.[@b29] This study was approved by the ethics committee of Qingdao Municipal Hospital (Qingdao, China). All the subjects included in this study were of the Chinese Northern Han population, and each signed a written informed consent form.

From June 2018 to December 2018, 225 unrelated adult Chinese Northern Han patients with NAFLD, of both genders, that were diagnosed by B-type ultrasonography were recruited. Among these NAFLD patients, 82 suffered from CAD (41 males, 41 females; mean age of 55.62 ± 7.187 years) and 142 did not have CAD (75 males, 67 females; mean age of 50.14 ± 11.842 years). A total of 152 healthy controls, matched for sex and age (75 males, 77 females; mean age of 51.38 ± 13.276 years) were included. All the patients were recruited from the Departments of Gastroenterology and Cardiology and the Health Examination Center of Qingdao Municipal Hospital.

Standard clinical evaluations of the NAFLD patients were performed according to the criteria of American Association for the Study of Liver Diseases.[@b21] Subjects with the following symptoms were excluded from the NAFLD cohort: 1) excessive alcohol intake (males \>210 g/w, females \>140 g/w); 2) viral hepatitis, such as hepatitis B or hepatitis C; 3) drug-induced hepatitis; 4) other endocrine and metabolic disorders, such as renal disease. CAD was diagnosed using the findings from percutaneous coronary angiogram conducted by two experienced interventional cardiologists, and defined as the presence of at least 50% stenosis in at least one of the coronary arteries. The healthy controls were also subjected to the same diagnosis routines for NAFLD and CAD, as well as the laboratory and general examinations.

Biochemical analyses {#s2-2}
--------------------

The basic clinical pathological information (gender, age, height, and weight) was obtained by a standard study questionnaire. The body mass index (BMI) was calculated as mass weight (kg)/height^2^ (m^2^). All the subjects underwent a 12-h overnight fast, and then the blood samples were collected into ethylene diaminetetraacetic acid-containing tubes. Serum fasting plasma glucose (FPG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyltransferase (r-GT), alkaline phosphatase (ALP), and bilirubin (BIL) were measured using standard clinical laboratory techniques.[@b30]

Genomic DNA extraction and genotyping {#s2-3}
-------------------------------------

Genomic DNA was extracted and stored as previously described.[@b31] The primers for PCR amplification containing rs780094 were 5′-ACGTTGGATGAAGTGGTGGGATTACAGGAG-3′ and 5′-ACGTTGGATGAGGGCCCCAGTTTTTTAGAC-3′, rs1260326 5′-ACGTTGGATGACCTGGGTCCCTTTGTCAC-3′ and 5′-ACGTTGGATGAGAAGACCAACCACATCCAG-3′ and were synthesized by Beijing BoMiao Biotech Company (China). The PCR amplification profile was as follows: predenaturation at 94°C for 5 m, followed by 40 cycles of denaturation at 94°C for 20 s, annealing at 56°C for 30 s, extending at 72°C for 60 s, followed by the final extension at 72°C for 3 m. The target amplified fragments were detected by 2% gel electrophoresis, with the predicted fragment length. The genotypes of rs780094 and rs1260326 were detected by direct DNA sequencing using the Applied Biosystems Inc. (USA) Veriti-384 Prism Sequence Detection System, and the raw data were analyzed using MassARRAY TYPER4.0 software (Agena Bioscience, USA). Genotyping was performed in a blinded fashion and the success rates were \>95%.

Statistical analysis {#s2-4}
--------------------

Statistical analysis was conducted using the SPSS 22.0 statistical software (SPSS Inc., USA). Student's *t*-test or χ^2^ test were used to analyzed the differences in characteristics of different groups. First, continuous variables were tested by normal distribution and F test; if yes, the baseline characteristics were expressed as the mean ± standard deviation (SD), and if no, the baseline characteristics were expressed as the median ± quartile. Hardy-Weinberg equilibrium was between expected and observed genotype distributions and was estimated using the χ^2^ test. Genotype and allele frequencies were assessed by counting the DNA sequencing data, and the distributions in NAFLD versus controls were analyzed by Pearson's χ^2^ test or Fisher's exact test, where appropriate. Association between polymorphisms and NAFLD/CAD were analyzed by logistic regression and odds ratios (ORs) with 95% confidence intervals (CIs). A *p*-value \<0.05 was considered statistically significant.

Results {#s3}
=======

Characteristics of the study participants {#s3-1}
-----------------------------------------

The baseline characteristics of the three groups (NAFLD, NAFLD with CAD, and healthy controls) according to the experimental requirements are shown in [Table 1](#t01){ref-type="table"}. There were no significant differences in age or gender among the three groups (all *p* \> 0.05). The increased serum levels of BMI, TC, TG, LDL, ALT, AST, and r-GT were observed in the NAFLD patients compared to the healthy controls (all *p* \< 0.05). In the NAFLD + CAD group, the BMI value and serum levels of FPG, TC, TG, LDL, ALT, AST, r-GT, and ALP were higher and the serum HDL level was lower than in healthy controls (all *p* \< 0.05). Compared to the NAFLD patients, the patients with NAFLD and CAD possessed higher serum levels of FPG, AST and ALP, and lower BMI value and serum levels of TC, HDL, and LDL (all *p* \< 0.05).

###### Baseline characteristics of the study participants[^a^](#table1fn1){ref-type="table-fn"}

  Characteristic   Controls         NAFLD            NAFLD + CAD      *p*       *p*~1~    *p*~2~    *p*~3~
  ---------------- ---------------- ---------------- ---------------- --------- --------- --------- ---------
  Age (y)          51.38 ± 13.276   50.14 ± 11.842   55.62 ± 7.187    0.156     \-        \-        \-
  Gender (F/M)     77/75            67/75            41/41            0.174     \-        \-        \-
  BMI (kg/m^2^)    23.45 ± 3.376    26.74 ± 2.805    25.24 ± 2.606    \<0.001   \<0.001   \<0.001   0.003
  FPG (mmol/L)     4.80 ± 1.479     5.00 ± 1.343     5.90 ± 2.180     \<0.001   0.010     \<0.001   0.001
  TC (mmol/L)      4.99 ± 1.192     5.48 ± 0.822     4.56 ± 1.274     \<0.001   0.010     \<0.001   \<0.001
  TG (mmol/L)      1.45 ± 1.009     1.90 ± 1.903     2.23 ± 4.396     \<0.001   0.003     \<0.001   1.000
  HDL (mmol/L)     1.28 ± 0.387     1.24 ± 0.198     1.05 ± 0.294     \<0.001   1.000     \<0.001   \<0.001
  LDL (mmol/L)     3.10 ± 0.708     3.27 ± 0.555     2.75 ± 0.972     \<0.001   0.034     0.006     \<0.001
  ALT (U/L)        19.90 ± 11.155   34.40 ± 26.165   28.90 ± 25.044   \<0.001   \<0.001   0.006     0.019
  AST (U/L)        21.93 ± 8.877    24.16 ± 8.994    44.67 ± 69.649   0.067     \-        \-        \-
  r-GT (mmol/L)    26.30 ± 24.367   39.63 ± 26.481   47.89 ± 85.986   \<0.001   \<0.001   0.010     0.019
  ALP (mmol/L)     75.14 ± 24.661   71.62 ± 18.272   85.79 ± 21.840   \<0.001   0.852     \<0.001   \<0.001
  BIL (mmol/L)     13.20 ± 5.358    13.30 ± 4.957    14.44 ± 7.020    0.475     \-        \-        \-

Abbreviations: NAFLD, patients with nonalcoholic fatty liver disease; NAFLD + CAD, patients with nonalcoholic fatty liver disease and coronary artery disease; BMI, body mass index; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; r-GT, glutamyltransferase; ALP, alkaline phosphatase; BIL, bilirubin.

*p*, controls vs. NAFLD vs. NAFLD + CAD ; *p*~1~, NAFLD vs. controls; *p*~2~, NAFLD + CAD vs. controls; *p*~3~, NAFLD + CAD vs. NAFLD.

Values are expressed as median ± quartile.

GCKR rs780094 and rs1260326 genotype and allele distribution {#s3-2}
------------------------------------------------------------

The genotype distributions of *GCKR* rs780094 and rs1260326 were in accordance with the Hardy-Weinberg equilibrium in each group (all *p* \> 0.05) ([Table 2](#t02){ref-type="table"}). As the results show in [Table 3](#t03){ref-type="table"}, there were no significant differences in the genotypic and allelic distributions of *GCKR* rs780094 and rs1260326 between the NAFLD patients and healthy controls, NAFLD + CAD patients and healthy controls, nor NAFLD + CAD patients and NAFLD patients, respectively (all *p* \> 0.05). These results suggested that *GCKR* rs780094 and rs1260326 polymorphisms did not associate with the risk of NAFLD in this Northern Chinese Han population, and *GCKR* rs780094 and rs1260326 polymorphisms did not increase the risk of CAD in these NAFLD patients.

###### Results of the Hardy-Weinberg equilibrium test[^a^](#table2fn1){ref-type="table-fn"}

  Gene locus groups   CC   CT   TT   χ^2^    *p* value
  ------------------- ---- ---- ---- ------- -----------
  **rs780094**                               
   Controls           26   81   45   1.040   0.308
   NAFLD              26   71   45   0.047   0.828
   NAFLD + CAD        18   39   25   0.014   0.708
  **rs1260326**                              
   Controls           23   82   46   1.890   0.169
   NAFLD              24   73   45   0.372   0.542
   NAFLD + CAD        15   41   26   0.028   0.868

Abbreviations: NAFLD, patients with nonalcoholic fatty liver disease; NAFLD + CAD, patients with nonalcoholic fatty liver disease and coronary artery disease.

Data were compared by chi-square test.

###### Distribution of the *GCKR* rs780094 and rs1260326 polymorphisms in the study groups[^a^](#table3fn1){ref-type="table-fn"}^,^[^b^](#table3fn2){ref-type="table-fn"}

  Genotype    Controls      NAFLD         NAFLD + CAD   OR (95%CI)             χ^2^    *p*~1~   OR (95%CI)             χ^2^    *p*~2~   OR(95%CI)              χ^2^    *p*~3~
  ----------- ------------- ------------- ------------- ---------------------- ------- -------- ---------------------- ------- -------- ---------------------- ------- --------
  rs780094                                                                                                                                                             
   CC         26 (17.1%)    26 (18.3%)    18 (22.0%)                                                                                                                   
   CT + TT    126 (82.9%)   116 (81.7%)   64 (78.0%)    0.837 (0.455--1.538)   0.073   0.787    0.734 (0.375--1.473)   0.819   0.365    1.255 (0.640--2.642)   0.437   0.509
  Alleles                                                                                                                                                              
   C          133 (43.8%)   123 (43.3%)   75 (45.7%)                                                                                                                   
   T          171 (56.2%)   161 (56.7%)   89 (54.3%)    0.982 (0.709--1.361)   0.012   0.914    1.083 (0.740--1.587)   0.169   0.681    1.103 (0.749--1.624)   0.247   0.619
  rs1260326                                                                                                                                                            
   CC         23 (15.1%)    24 (16.9%)    15 (18.3%)                                                                                                                   
   CT + TT    129 (84.9%)   118 (83.1%)   67 (81.7%)    0.877 (0.470--1.636)   0.171   0.679    1.256 (0.615--2.565)   0.351   0.532    0.908 (0.446--1.850)   0.07    0.791
  Alleles                                                                                                                                                              
   C          128 (42.1%)   121 (42.6%)   71 (43.3%)                                                                                                                   
   T          176 (57.9%)   163 (57.4%)   93 (56.7%)    1.021 (0.736--1.416)   0.015   0.902    1.050 (0.715--1.541)   0.061   0.804    1.028 (0.698--1.516)   0.02    0.887

Abbreviations: NAFLD, patients with nonalcoholic fatty liver disease; NAFLD + CAD, patients with nonalcoholic fatty liver disease and coronary artery disease.

Data were compared by chi-square test.

Values are expressed as *n* (%).

Association of GCKR polymorphisms with clinical parameters in each group {#s3-3}
------------------------------------------------------------------------

The effects of *GCKR* rs780094 T or rs1260326 T allele on the clinical characteristics of NAFLD patients, NAFLD + CAD patients, and overall series were analyzed. As the results show in [Table 4](#t04){ref-type="table"} and [Table 5](#t05){ref-type="table"}, the BMI value and serum FPG and TG levels were significantly lower in the rs780094 T and rs1260326 T allele carriers than in the non-carriers in the overall series (all *p* \< 0.05), respectively. In addition, the serum level of FPG in rs780094 T carriers was higher than in non-carriers in the NAFLD + CAD group (*p* \< 0.05). No marked difference of other clinical parameters was observed between the carriers and non-carriers of the rs780094 T or rs1260326 T allele in each group (*p* \> 0.05). Multivariate logistic regression analysis showed that *GCKR* rs780094 is the dependent factor associated with FPG (*p* \< 0.05).

###### Clinical characteristics of *GCKR* rs780094 T carriers and non-carriers in the study population[^a^](#table4fn2){ref-type="table-fn"}

  Characteristic   Controls        NAFLD           NAFLD + CAD                                                                                                                                                                                         
  ---------------- --------------- --------------- ---------------------------------------------- --------------- --------------- ---------------------------------------------- ----------------------------------------------------- --------------- ----------------------------------------------
  BMI (kg/m^2^)    22.91 ± 4.36    24.44 ± 3.40    0.001                                          26.35 ± 3.50    27.05 ± 5.87    0.659[^\#^](#table4fn1){ref-type="table-fn"}   25.29 ± 2.422                                         25.05 ± 3.250   0.73[^\#^](#table4fn1){ref-type="table-fn"}
  FPG (mmol/L)     4.45 ± 1.00     4.74 ± 1.00     0.043                                          4.74 ± 0.65     4.86 ± 0.60     0.405                                          5.18 ± 1.38                                           6.04 ± 3.16     0.001
  TC (mmol/L)      5.04 ± 1.00     5.09 ± 2.00     0.860                                          5.49 ± 1.03     5.48 ± 1.28     0.947                                          4.52 ± 1.236[^\#^](#table4fn1){ref-type="table-fn"}   4.69 ± 1.430    0.616[^\#^](#table4fn1){ref-type="table-fn"}
  TG (mmol/L)      1.08 ± 1.00     1.64 ± 2.00     0.002                                          1.53 ± 1.01     1.75 ± 1.19     0.252                                          1.49 ± 1.20                                           1.65 ± 1.33     0.751
  HDL (mmol/L)     1.29 ± 0.00     1.15 ± 0.00     0.297                                          1.23 ± 0.27     1.23 ± 0.21     0.325                                          1.03 ± 0.33                                           1.06 ± 0.28     0.396
  LDL (mmol/L)     3.07 ± 0.697    3.23 ± 0.754    0.295[^\#^](#table4fn1){ref-type="table-fn"}   3.25 ± 0.547    3.36 ± 0.586    0.349[^\#^](#table4fn1){ref-type="table-fn"}   2.74 ± 0.948                                          2.78 ± 1.083    0.866[^\#^](#table4fn1){ref-type="table-fn"}
  ALT (U/L)        16.83 ± 11.00   19.29 ± 11.00   0.996                                          24.81 ± 23.66   21.77 ± 40.27   0.950                                          22.78 ± 18.59                                         20.41 ± 13.03   0.320
  AST (U/L)        22.73 ± 6.00    20.33 ± 6.00    0.247                                          22.20 ± 8.50    20.38 ± 13.11   0.527                                          21.30 ± 18.61                                         20.34 ± 15.07   0.251
  r-GT (mmol/L)    18.89 ± 13.00   22.02 ± 14.00   0.143                                          29.40 ± 26.76   37.35 ± 23.79   0.294                                          25.62 ± 16.73                                         23.19 ± 16.95   0.406
  ALP (mmol/L)     69.92 ± 26.00   77.06 ± 36.00   0.417                                          66.87 ± 24.07   74.80 ± 22.73   0.056                                          79.85 ± 23.10                                         84.77 ± 28.11   0.809
  BIL (mmol/L)     12.70 ± 6.00    11.50 ± 4.00    0.432                                          11.90 ± 5.10    12.30 ± 3.60    0.587                                          13.05 ± 6.15                                          12.65 ± 5.20    0.397

Abbreviations: NAFLD, patients with nonalcoholic fatty liver disease; NAFLD + CAD, patients with nonalcoholic fatty liver disease and coronary artery disease.

Values are expressed as mean ± SD and compared by Student's *t* test.

Values are expressed as median ± quartile.

###### Clinical characteristics of *GCKR* rs1260326 T carriers and non-carriers in the study population[^a^](#table5fn2){ref-type="table-fn"}

  Characteristic                                        Controls        NAFLD           NAFLD + CAD                                                                                                                                                   
  ----------------------------------------------------- --------------- --------------- ---------------------------------------------- --------------- --------------- ---------------------------------------------- --------------- --------------- ----------------------------------------------
  BMI (kg/m^2^)                                         22.96 ± 4.35    24.46 ± 3.81    0.003                                          26.35 ± 3.48    27.05 ± 6.06    0.665[^\#^](#table5fn1){ref-type="table-fn"}   25.27 ± 2.616   25.11 ± 2.648   0.836[^\#^](#table5fn1){ref-type="table-fn"}
  FPG (mmol/L)                                          4.49 ± 1.00     4.76 ± 1.00     0.054                                          4.75 ± 0.67     4.86 ± 0.56     0.586                                          5.22 ± 1.43     6.02 ± 3.15     0.051
  TC (mmol/L)                                           5.03 ± 1.00     5.13 ± 2.00     0.896                                          5.44 ± 1.00     5.89 ± 4.33     0.713                                          4.51 ± 1.224    4.76 ± 1.506    0.496[^\#^](#table5fn1){ref-type="table-fn"}
  TG (mmol/L)                                           1.08 ± 1.00     1.61 ± 2.00     0.006                                          1.54 ± 1.00     1.75 ± 1.17     0.366                                          1.46 ± 1.23     1.88 ± 1.21     0.710
  HDL (mmol/L)                                          1.29 ± 0.00     1.12 ± 0.00     0.260                                          1.23 ± 0.28     1.23 ± 0.21     0.369                                          1.03 ± 0.33     1.06 ± 0.30     0.564
  LDL (mmol/L[^\#^](#table5fn1){ref-type="table-fn"})   3.08 ± 0.708    3.20 ± 0.709    0.446[^\#^](#table5fn1){ref-type="table-fn"}   3.25 ± 0.542    3.37 ± 0.61     0.324[^\#^](#table5fn1){ref-type="table-fn"}   2.72 ± 0.935    2.85 ± 1.15     0.635[^\#^](#table5fn1){ref-type="table-fn"}
  ALT (U/L)                                             16.81 ± 11.00   19.70 ± 10.00   0.729                                          24.81 ± 22.52   21.77 ± 42.58   0.918                                          22.70 ± 18.14   22.63 ± 15.31   0.488
  AST (U/L)                                             20.30 ± 6.00    22.91 ± 6.00    0.085                                          22.20 ± 8.27    20.38 ± 14.61   0.647                                          21.29 ± 18.39   20.36 ± 20.79   0.358
  r-GT (mmol/L)                                         18.79 ± 13.00   22.30 ± 13.00   0.135                                          29.40 ± 25.59   37.35 ± 27.63   0.296                                          25.79 ± 16.92   22.91 ± 14.91   0.503
  ALP (mmol/L)                                          69.71 ± 26.00   80.25 ± 32.00   0.257                                          66.87 ± 22.96   75.67 ± 23.55   0.040                                          80.20 ± 23.36   80.02 ± 30.26   0.802
  BIL (mmol/L)                                          12.50 ± 6.00    11.70 ± 5.00    0.593                                          11.90 ± 6.00    12.30 ± 3.80    0.636                                          13.10 ± 5.70    11.10 ± 5.20    0.400

Abbreviations: NAFLD, patients with nonalcoholic fatty liver disease; NAFLD + CAD, patients with nonalcoholic fatty liver disease and coronary artery disease.

Values are expressed as mean ± SD and compared by Student's *t* test.

Values are expressed as median ± quartile.

Discussion {#s4}
==========

NAFLD can be caused by many risk factors, such as diet, genetics and so on. Genetic susceptibility genes are a type of risk factor that can contribute to the development of NAFLD. In this study, we investigated the relationship between *GCKR* rs780094 and rs1260326 gene polymorphisms and the risk of NAFLD in a general Chinese Northern Han population, and the risk of CAD in NAFLD patients in this population for the first time. Our results showed that the genotype distributions of *GCKR* rs780094 and rs1260326 were not associated with the risk of NAFLD, and not associated with the risk of CAD in NAFLD patients in this Chinese Northern Han population. In addition to the BMI value and serum FPG and TG levels, the T allele of *GCKR* rs780094 and rs1260326 also did not significantly affect the clinical parameters in NAFLD patients and NAFLD + CAD patients. These data suggest that *GCKR* rs780094 and rs1260326 polymorphisms are not associated with the risk of NAFLD in the general Chinese Northern Han population, and *GCKR* rs780094 and rs1260326 polymorphisms do not increase the risk of CAD in NAFLD patients in the Chinese Northern Han population.

Accumulated studies have explored the effects of *GCKR* polymorphisms on the risk of NAFLD but the results have been inconsistent.[@b16]--[@b18],[@b32] Some previous studies and our study suggested that *GCKR* rs780094 and rs1260326 polymorphisms are not associated with the risk of NAFLD, the probable reason for this finding may be due to the ethnic differences among the NAFLD patients studied. The relationship between *GCKR* polymorphism and NAFLD or nonalcoholic steatohepatitis may be modified by the change and confluence of race, therefore the effects of a *GCKR* polymorphism may become more dominant and significant in European populations than they are in Asian populations. Therefore, the *GCKR* rs780094 T allele might increase the risk of NAFLD in European populations but not in Asian populations.[@b15],[@b17],[@b18],[@b33] A higher prevalence of NAFLD has been observed in some Indians that possess European ancestry, as opposed to those that possess Asian ancestry, which might explain the above hypothesis.[@b34]

The *GCKR* gene encodes GCKRP, an enzyme that plays a regulatory role in hepatic GCK activity.[@b35],[@b36] The *GCKR* rs1260326 functional variant P446L increases GCK activity by down-regulating the level of fructose 6-phosphate.[@b37] Increased GCK activity is tightly accompanied by elevated hepatic glycolytic flux, *de novo* lipogenesis, and hepatic TG level.[@b13],[@b38] In this study, our results showed that the *GCKR* rs780094 and rs1260326 T allele were significantly associated with decreasing serum FPG level among the overall patients and the NAFLD + CAD patients. These results suggest that *GCKR* rs780094 and rs1260326 may repress the activity of GCKRP to decrease the serum FPG level.

Previous studies also investigated the association of *GCKR* polymorphisms with the risk of CAD. In a dietary intervention study, Shen *et al.*[@b39] found that the *GCKR* rs1260326 T allele may increase the risk of atherosclerosis. Lian *et al.*[@b40] demonstrated the positive association of *GCKR* rs780093 with the risk of CAD in an older Chinese Han population, through a case-control study. On the contrary, Járomi *et al.*[@b41] did not detect any association of *GCKR* rs1260326 with the susceptibility of stroke. Bi *et al.*[@b42] also found that the *GCKR* rs780094 SNP had no significant association with the incidence of CAD or stroke. SNPs of *GCKR* rs780094 showed strong linkage disequilibrium with rs1260326.[@b24],[@b39],[@b40] Our results showed that *GCKR* rs780094 and rs1260326 genotype distributions were not associated with the occurrence of CAD in NAFLD patients but that the rs780094 T allele could decrease the serum FPG levels in the NAFLD + CAD group. These results indicated that *GCKR* rs780094 and rs1260326 were not the risk factor of CAD in NAFLD patients but that the rs780094 T allele could affect serum FPG level in the NAFLD + CAD patients of our Chinese Northern Han population.

Some limitations of our study should be acknowledged. First, all the subjects in this study were of the Chinese Northern Han population, so that the applicability of our conclusion to other ethnic populations requires further study for confirmation. Second, ultrasonography was used to diagnose NAFLD because of the difficulty in conducting liver biopsy. Third, our study did not grade the severity of NAFLD patients. Finally, a greater number of subjects should be included in the further studies to verify this conclusion in the Chinese Han population and other ethnic populations.

Conclusions {#s5}
===========

In summary, we investigated the relationship of *GCKR* rs780094 and rs1260326 gene polymorphisms with the risk of NAFLD as well as the risk of CAD in NAFLD patients in the Chinese Northern Han population. We concluded that *GCKR* rs780094 and rs1260326 gene polymorphisms did not associate with the risk of NAFLD nor with the risk of CAD in NAFLD patients in the Chinese Northern Han population. In addition, the *GCKR* rs780094 T and rs1260326 T alleles did affect the BMI value and serum FPG and TG levels in the overall subjects and NAFLD + CAD patients.
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:   aspartate aminotransferase
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GCK
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PCR
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